Dignitana

Revenue reaches record high with EBITDA positive

Financial highlights Q1 2023

• Net sales amounted to 21.5 MSEK (15.9), an increase of 35 percent over the same period in 2022.
• Operating result amounted to -3.5 MSEK (-6.1).
• Net result after financial items amounted to -3.9 MSEK (-6.5).
•  Earnings per share were -0.06 SEK (-0.10).
• Cash Balance amounted to 11.7 MSEK (11.3).
• Average Daily Treatment Revenue (ADTR)* was 242 TSEK (179), an increase of 35 percent over the same period in 2022.
• EBITDA positive for the period.

Business highlights during the period

• In March Dignitana AB signed Science International Corporation, a leading distributor for medical devices, to launch The DigniCap Scalp Cooling System in Hong Kong and Macao.
• In the first period Dignitana exhibited at two conferences, Onkologidagarna in Sweden and National Consortium of Breast Centers in the US, where a session on DigniCap was also presented by a customer.
• Dignitana’s prominent visibility in the breast cancer community continued with the Susan G. Komen® More Than Pink Walk in West Palm Beach, Florida in January.

Business highlights after the period

• Dignitana exhibited at the Oncology Nursing Congress in San Antonio, Texas.

Key Figures

*ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

“The evidence of DigniCap Delta’s efficacy, ease of use and patient happiness are supported by extraordinary customer satisfaction and a patient recommendation score of 97 percent.” - Catarina Löwenadler, CEO Dignitana AB

All financial reports are available at www.dignitana.com/investor-relations/financial-reports/